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Background: Lipid accumulation is the primary evidence of non-alcoholic fatty liver disease (NAFLD). Ginkgo
biloba extract (GBE) and its flavonoid ingredients (quercetin, kaempferol, and isorhamnetin) could lessen the lipid
accumulation associated with up-regulation of the rate-limiting enzyme, carnitine palmitoyltransferase 1A (CPT1A),
in the β-oxidation of long-chain fatty acids. In this study, we investigated the mechanisms by which GBE and its
flavonoids induced expression of CPT1A.
Results: CPT1A inhibition with RNAi resulted in triglyceride accumulation in HepG2 cells. Through deletion and
mutation analysis of CPT1A’s promoter combined with electrophoretic mobility shift assay (EMSA) and chromatin
immunoprecipitation (ChIP) experiments, the CPT1A promoter region (−50 to −5 nt) was determined to contain
two putative Sp1 binding sites, namely Sp1a and Sp1b, which might act as the GBE regulation response DNA
element. Sp1 might be induced to transfer from cytoplasma to nucleus to bind the promoter region of −50 to −5
nt by GBE. The regulatory effects of GBE on CPT1A were also verified on the flavonoid ingredients quercetin,
kaempferol, and isorhamnetin.
Conclusion: Sp1 was crucial in regulating CPT1A expression with GBE and its flavonoid ingredients, and the −50
to −5 nt region of CPT1A promoter played important roles in Sp1 binding.
Keywords: Ginkgo biloba extract (GBE), CPT1A, Sp1, Flavonoid ingredients, RegulationBackground
Non-alcoholic fatty liver disease (NAFLD) is characterized
by triglyceride (TG) accumulation in hepatocytes and is
commonly associated with dyslipidemia, hypertension,
obesity, and hyperglycemia. To date, there are no ideal
NAFLD treatment options. Traditional strategies mainly
focus on lifestyle modification and body weight loss, simply
slowing steatosis with no long-term efficacy [1]. Although
various drugs were under investigation, efficacy and safety
profiles remained uncertain, and no proven treatments
have yet been approved [2].* Correspondence: qhzhang@wayenbio.com
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unless otherwise stated.Ginkgo biloba has been used for hundreds of years in
China to treat various disorders. EGb761, Ginkgo biloba
leaf extract, is widely used as a dietary supplement or
phytomedicine currently in western countries. Ginkgo
biloba extract (GBE) mainly consists of two groups of
active components: flavonoid and terpenoid [3]. Our
previous work has shown that GBE regulates lipid me-
tabolism and lessens the lipid accumulation in the livers
of rats fed a high-fat diet (HFD) or hepatocytes at the
transcriptome regulation level. GBE, with its flavonoid
ingredients, could significantly up-regulate expression of
carnitine palmitoyltransferase 1A (CPT1A), a rate-limiting
enzyme in the β-oxidation of long-chain fatty acids
(LCFAs), and elevate its activity [4,5]. However, the
mechanisms of regulation in CPT1A expression remained
uncertain.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Wei et al. Journal of Biomedical Science 2014, 21:87 Page 2 of 11
http://www.jbiomedsci.com/content/21/1/87CPT1 is located in the outer mitochondrial membrane
and facilitates the transport of long-chain fatty acids into
the mitochondria for β-oxidation by converting them
from acyl-CoA into acyl-carnitine [6]. In the liver,
CPT1A is the primary isoform expressed while CPT1B
and CPT1C specifically distribute into muscle, heart,
and brain [7,8]. Alteration of CPT1A occurs in response
to lipid metabolites, hormones, nutrition, among others.
Soy isoflavones and L-carnitine regulate CPT1A activity
in HepG2 cells positively [9]. Peroxisome proliferator-
activated receptor α (PPARα) rapidly increases CPT1A
expression in rat [10]. Moderate increases in CPT1A ac-
tivity causes profound effects on fatty acid oxidation and
is sufficient to reduce hepatic triglyceride accumulation,
both in vivo and in vitro, with an unexpected mitigating
effect on lipid-induced insulin resistance [11-13].
In the present study, we focused on the regulation of
CPT1A expression by GBE, and attempted to reveal its
underlying mechanisms. Thus, RNAi technology was
used to evaluate the role of CPT1A in GBE’s effect. In
addition, nucleotide deletion and mutation analysis of a
CPT1A promoter combined with electrophoretic mobil-
ity shift assay (EMSA) and chromatin immunoprecipita-
tion (ChIP) experiments were conducted to identify the
specific responsive element of GBE and its flavonoids.
Our results finally revealed an Sp1 binding region lo-
cated in the CPT1A promoter was critical for the regula-
tion of CPT1A by GBE.
Methods
Cell culture and treatment
The human hepatocellular carcinoma cell line, HepG2,
was kindly gifted by the Chinese National Human Gen-
ome Center at Shanghai. HepG2 cells were cultured in
Minimum Essential Medium (MEM) (Invitrogen, Carlsbad,
CA, USA) containing 10% fetal bovine serum (FBS) (Invi-
trogen) at 37°C in a 5% CO2 incubator. GBE was provided
by Shanghai Xingling Science and Technology Pharma-
ceutical Co., Ltd. (Shanghai, China) as a standardized
product that contained approximately 24% flavonol glyco-
sides, 6% terpenelactones (ginkgolides, bilobalide), and
less than 5 parts per million (ppm) of ginkgolic acid.
Quercetin, kaempferol, and isorhamnetin were purchased
from Shanghai Tauto Biotech Co., Ltd. (Shanghai, China).
For experiments, cells were seeded into a 24-well plate
at a density of 1 × 105 cells per well and incubated to
reach about 70% confluence. Cells were then treated
with MEM-2% FBS containing one of the following:
200 μg/ml GBE (G200), 20 μg/ml quercetin (Q20),
20 μg/ml kaempferol (K20), or 8 μg/ml isorhamnetin
(I8) for 12 or 24 hours. The concentrations of the flavo-
noids were set according to their respective proportions
in GBE. As control, 0.1% dimethyl sulfoxide (DMSO, D)
was used.Cellular triglyceride content measurement
The cellular triglyceride content was measured as before
[5]. After 24 hours of treatment, the harvested cells were
washed with 1 × PBS, suspended in 500 μl isopropanol
with sonication for 30 minutes and stood on ice for
1 hour. Then, samples were centrifuged at 13,200 rpm
for 10 minutes at 4°C. The extracted supernatants were
evaporated in a vacuum centrifuge concentrator and re-
suspended in 20 μl isopropanol for further cellular tri-
glyceride content measurement using Total Triglyceride
Detection Kit (Shanghai Kehua Bio-Engineering Co.,
Ltd., Shanghai, China). Meanwhile, the precipitates were
lysed by RIPA lysis buffer (Beyotime, Haimen, Jiangsu,
China), and total protein level was determined by BCA
Protein Assay Kit (Beyotime). Triglyceride content (TG)
was normalized to corresponding total protein.RNA extraction and real time RT-PCR
The total RNA was extracted from cells using TRIzol re-
agent (Invitrogen) according to the standard protocol.
The purity and concentration of the extracted RNA sam-
ples were examined by a 2100 Bioanalyzer and the RNA
6000 LabChipR (Agilent Technologies, Santa Clara, CA,
USA). Real-time RT-PCR was carried out on an ABI
PRISM 7300 Sequence Detector (Applied Biosystems,
Foster City, CA, USA) using SYBR green I fluorescent dye
(Toyobo, Osaka, Japan). The primers used were as follows:
For CPT1A (GenBank: NM_001876): forward, 5′-CGGTT
GCTGATGACGGCTAT; reverse, 5′-CAAAGCGATGA
GAATCCGTC, and for Sp1 (GenBank: NM_00125182
5.1): forward, 5′-CTGCCACCATGAGCGACCAAG; re-
verse, 5′- CTGATCTCAGAAGCCATTGC. For data ana-
lysis, a method designated as 2-ΔΔCT was used to calculate
fold change. β-actin was used as an internal control. All
samples were performed in triplicate, and the final data
represented the mean of at least three individual
experiments.Western blot
Whole-cell lysates prepared by RIPA lysis buffer (Beyo-
time) from HepG2 cells were separated by SDS-PAGE
and then transferred onto PVDF membranes (Millipore,
Billerica, MA, USA). The membranes were probed with
anti-β-actin (1:2000; Proteintech, Chicago, IL, USA) or
anti-CPT1A (1:250; Santa Cruz Biotechnology, Santa
Cruz, CA, USA) and horseradish peroxidase (HRP) con-
jugated secondary antibody (1:2000; Santa Cruz Bio-
technology) and then detected using ECL reagents (GE
Healthcare, Piscataway, NJ, USA) by imaging systems.
Nuclear and cytoplasmic proteins were extracted separ-
ately, while α-tubulin and histone H3 were used as in-
ternal controls.
Table 2 Sequences of wild-type and mutant CPT1A
promoter constructs in mutational analysis






aPutative cis-elements were indicated with capital, and introduced mutations
were shown in bold.
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mutagenesis
A series 5′-deletion fragments of the human CPT1A
promoter with KpnI/HindIII restriction sites were PCR-
amplified from human genomic DNA (Table 1), and con-
structed into KpnI/HindIII sites of pGL3-Basic vector
(Promega, Madison, WI, USA) in front of the luciferase
reporter gene. Three site-directed mutated constructs
were also used to determine the responsive element of
GBE and its flavonoids (Table 2). All constructs were vali-
dated with DNA sequencing.
Transient transfection and luciferase assays
Lipofectamine™ 2000 (Invitrogen) was used for in vitro
transfection of all the experimental vectors according to
standard protocols. Briefly, 1 × 105 HepG2 cells were
seeded into 24-well culture plates and grown overnight
to 80-90% confluence. For luciferase activity assays,
0.5 μg of reconstructed CPT1A-promoter reporter plas-
mids along with 10 ng of PRL-SV40 plasmids that
encoded renilla luciferase for normalization were co-
transfected into each well. Twenty-four hours after
transfection, the culture media was changed with or
without GBE for a continuous 24 hours. After treatment,
cell lysates were collected and assayed for luciferase activ-
ity using a Dual-Luciferase Reporter Assay kit (Promega).
RNA interference
Four shRNAs were designed to target the coding se-
quences of human CPT1A and cloned into pGPU6/GFP/
Neo vectors (Table 3). Vectors without influence on the
expression of CPT1A were also produced as negative con-
trol (NC). siRNA-Sp1 (5′-GCUCCAGAUCCAGUAUCU
UTT-3′) was used to target Sp1. All shRNAs and siRNA-
Sp1 were synthesized by Shanghai GenePharma Co., Ltd.
(Shanghai, China).
For RNAi, cells in each well were transfected with a
mixture of 0.8 μg shRNA plasmids plus 2 μl Lipofecta-
mine™ 2000 reagents. Medium was changed with or










pCPT1A-3 ~ 6/Luc_R CCCAAGCTTGTCTGTTCCCAGGGCTCTTC
a_R: reverse primer, _F: forward primer.Afterwards, cells were harvested for mRNA determin-
ation after continuous 12-hour or 24-hour incubation
for western blotting analysis and cellular triglyceride
content measurement.Electrophoretic mobility shift assay (EMSA)
Nuclear proteins were extracted using Nuclear and
Cytoplasmic Protein Extraction Kit (Beyotime) after
6 hours of treatment with or without GBE. For each
sample, 6 μg nuclear proteins were pre-incubated with
the EMSA/Gel-Shift Binding Buffer (Beyotime) to block
non-specific binding for 15 minutes at 4°C prior to the
addition of the biotin-labeled probe (100 pmol) which
corresponded to the −50 to −5 nt of CPT1A promoter
region and further incubation for 20 minutes at 25°C.
For supershifts, nuclear extracts were pre-incubated with
3 μg of antibodies against Sp1 (Abcam, Cambridge, UK)
or non-immune IgG (Santa Cruz Biotechnology) (nega-
tive control) for 15 minutes at 4°C prior to addition of
the labeled probe. Electrophoresis was carried out on
non-denaturating polyacrylamide gels (6%) in 0.5 × TBE
at 100 V for 90 minutes and then electrophoretically
transferred onto a positively-charged nylon membrane
in 0.5 × TBE at 380 mA for 45 minutes. The membrane
was cross-linked at 120 mJ/cm2. The DNA-protein com-
plex was visualized with streptavidin-HRP Conjugate
(Beyotime) according to the manufacturer’s instructions.Table 3 Sense sequences of the oligonucleotides for
synthesized shRNAs
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Sp1 binding activity to the CPT1A promoter region in
intact cells was confirmed using a ChIP assay kit (Beyo-
time). Briefly, 2 × 107 HepG2 cells were treated with D,
G200, Q20, K20 or I8 for 6 hours and then cross-linked
in 1% formaldehyde solution for 10 minutes at 37°C.
Cross-linking was stopped by the addition of glycine to a
final concentration of 125 mM. After 5 minutes, the
cells were washed twice with 1 × PBS and harvested with
PBS containing 100 mM PMSF. The cells were lysed and
sonicated on ice with a Sonifier (Measuring and Scien-
tific Equipment, UK) at 7 W for nine 10-second pulses
and then centrifuged. After centrifugation, 20 μl of su-
pernatants were used to measure total input chromatin
(input control) and the rest were incubated in a rotor
with 4 μg of anti-Sp1 antibody (Abcam) or normal-
rabbit IgG (Santa Cruz Biotechnology) at 4°C overnight.
Fifty μl of Dynabeads® Protein A beads (Invitrogen) were
added for further 1.5 hours incubation the next day.
Then the immunoprecipitated DNA-protein complexes
were washed, eluted, and purified to conduct PCR for
forty cycles. The PCR primers for ChIP assay (forward,
5′-CTCGGCGTCCCCACAG-3′; reverse, 5′-TTCCCAG
GGCTCTTCG-3′) were designed to flank the Sp1 bind-
ing sites of the −50 to −5 of CPT1A promoter region,
and the PCR products were analyzed on 2% agarose gel.
Statistical analysis
Data were presented as the means ± SD. The statistical
analyses were performed using an unpaired, two-tailed
Student’s t test. The significance of differences were indi-
cated as * P < 0.05 and ** P < 0.01.
Results
CPT1A enhanced the lipid-lowering effect of GBE and its
flavonoids
Considering the complexity and pleiotropy of herbal
medicine, we first investigated whether the lipid-lowering
effect of GBE was completely dependent on CPT1A. RNA
interference technology was adopted to silence endogen-
ous CPT1A expression, and two shRNA vectors with up
to 85% silence efficiency were selected out for continued
experimentation (Figure 1A).
We observed a significant up-regulation of CPT1A by
GBE in NC group cells when GBE or the flavonoids were
added after transfection for 24 hours, while no influence
was shown in the group silenced by shRNA1. The re-
sults indicated that the regulatory ability of GBE and its
flavonoids on CPT1A was abolished when CPT1A was
knocked down (Figure 1A). Western blotting results
also confirmed a remarkable decrease in CPT1A protein
and no compensation effect by drug treatment (Figure 1B).
More strikingly, knockdown of CPT1A caused a high in-
crease in cellular TG content by approximately 40% whileGBE treatment slightly reduced the previous increase, sug-
gesting the existence of alternative pathways. This regula-
tion was, however, much weaker than that in NC cells,
and cellular TG content remained notably high. In exam-
ining the three flavonoid ingredients, we found quercetin
and kaempferol exhibited the similar results as GBE. In
contrast, isorhamnetin lost most of the lipid-lowering ef-
fect when endogenous CPT1A’s expression was inhibited
(Figure 1C). Experiments with shRNA2 achieved the same
results (data not shown).
CPT1A promoter region from −50 to −5 nt was critical for
GBE-induced regulation
We had confirmed previously that GBE significantly
promoted the expression of CPT1A in HepG2 cells. To
further define the transcriptional regulation mechanisms
of CPT1A, a series of luciferase reporter plasmids were
constructed (Figure 2A) and transfected into HepG2
cells. As shown in Figure 2B, in the presence of GBE, ac-
tivities of pCPT1A-1/Luc and pCPT1A-3/Luc constructs
were enhanced by 1.5 to 1.7 fold, indicating that the re-
gion −426 to +38 was indispensable for GBE regulation.
With the pCPT1A-5/Luc (−51 to +38) construct, we ob-
served the activity was 1.6-fold higher in the presence of
GBE, while there was no such effect with the pCPT1A-6/
Luc (−4 to +38) construct. Thus, we deduced that GBE-
regulatory elements would be within the region −50 to −5.
The same results could be obtained with the flavonoids,
the active ingredients of GBE (Figure 2C).
Mutation of Sp1 binding sites in the CPT1A promoter
region affected the responsiveness of GBE
Computer-aided analysis (TESS, http://www.cbil.upenn.
edu/cgi-bin/tess/tess; promoter scan, http://www-bimas.
cit.nih.gov/molbio/proscan/; Tfsitescan, http://www.ifti.
org/cgi-bin/ifti/Tfsitescan.pl) revealed two important pu-
tative Sp1 binding sites in the −50 to −5 of CPT1A pro-
moter region, Sp1a (−44 to −35) and Sp1b (−18 to −9),
respectively.
We first investigated whether GBE could induce tran-
scription of the construct contained −50 to −5 of CPT1A
promoter region (pCPT1A/WT) without Sp1. We de-
signed an siRNA-Sp1 to knockdown Sp1 with about
60% inhibition efficiency detected by RT-PCR (Additional
file 1: Figure S1A). As shown in Figure 3A, there was
no improvement in activity of pCPT1A/WT when Sp1
was inhibited, while GBE highly enhanced its activity
by 1.4 fold when Sp1 was present. The flavonoids –
quercetin, kaempferol, and isorhamnetin – also showed
the same results that Sp1 played an important role in
this regulation.
Furthermore, to define the role of Sp1a and Sp1b in
GBE-inducible CPT1A transcription, substitute mutations
were introduced into their core sequences (Figure 3B).
Figure 1 Knockdown of CPT1A influenced the lipid-lowering effect of Ginkgo biloba extract (GBE) and its ingredients in HepG2 cells.
(A) CPT1A expression regulated by GBE and its flavonoids in NC- and shRNA- cells. The mRNA expression of CPT1A was normalized to β-actin.
**P < 0.01 versus DMSO treatment in NC group. (B) CPT1A protein expression in NC- and shRNA- cells. Vectors without influence on the
expression of CPT1A were negative controls (NC). (C) Cellular triglyceride content regulated by GBE and its flavonoids in NC- and shRNA- cells.
The cellular triglyceride content in NC group with DMSO treatment was set at 100%, and values in other groups were compared to it. *P < 0.05
versus DMSO treatment in NC group. #P < 0.05 versus DMSO treatment in shRNA group. D, G200, Q20, K20, I8 represented HepG2 cells incubated
with 0.1% DMSO, 200 μg/ml GBE, 20 μg/ml quercetin, 20 μg/ml kaempferol, and 8 μg/ml isorhamnetin, respectively.
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while the Sp1b mutation caused little effect. Moreover,
mutation of Sp1a and Sp1b at the same time induced
even more remarkable changes (Figure 3C). Investiga-
tions on the flavonoids also revealed that pCPT1A/Ma
and pCPT1A/Mab constructs containing an Sp1a muta-
tion were unresponsive to the flavonoids while the
pCPT1A/Mb construct containing a mutation in Sp1b
displayed little effect in induced luciferase activity
(Figure 3D). Among the three ingredients, kaempferol
and isorhamnetin showed a relatively higher activity
than quercetin. Taken together, Sp1 sites – especially
Sp1a in the region of −50 to −5 – were essential to the
up-regulation of human CPT1A by GBE and its flavon-
oid ingredients.GBE enhanced Sp1 transfer from cytoplasm to nucleus
To investigate the regulation of Sp1 by GBE, RT-PCR and
western blotting were performed. No striking changes
were observed on whole mRNA and protein expression of
Sp1 (Figure 4A and B). However, we detected an obvious
transfer of Sp1 from cytoplasm to nucleus by western
blotting in a time-dependent manner upon GBE treat-
ment, especially at 24 hours (Figure 4C). Thus, GBE might
increase the content of Sp1 in the nucleus through in-
duced transfer from cytoplasm, in addition to directly en-
hanced its expression.GBE promoted Sp1 binding to the promoter region of
CPT1A
To determine whether or not GBE can affect Sp1 binding
to CPT1A’s promoter region, EMSA was performed using
nuclear extracts from HepG2 and a biotin-labeled probe
covering the −50 to −5 of CPT1A promoter region. DNA-
protein complex revealed bands C1 and C2 after incu-
bation (Figure 5A, lane 2). However, GBE-treated cell
nuclear lysates had significant increases in C1 formation
but no obvious influence on C2 (Figure 5A, lane 3). The
binding bands were specifically competed by 100-fold
molar excess unlabeled (cold) probes (Figure 5A, lane 4).
Above observations indicated that GBE promotes Sp1
binding to the CPT1A promoter region. It was also vali-
dated by supershift assays. Labeled Sp1 consensus probe
was used as positive control. Anti-Sp1 antibody incubation
resulted in a supershift band (ss) (Figure 5B, lane 2 and 5),
while negative IgG did not (Figure 5B, lane 3 and 6). With
ChIP assay, more PCR products could be detected in GBE
or its ingredients treated HepG2 cells. While the input
samples gave the same yields, no PCR product was de-
tected without applying Sp1 antibody (Figure 5C).
Discussion
Currently, although treatment of NAFLD by diet control
and body weight loss results in histological improvement,
pharmacotherapeutic options are lacking and remain fo-
cused on treating concurrent metabolism syndrome [14].
Figure 2 Mapping of the GBE-responsive region in human CPT1A promoter region. (A) A promoter fragment of the CPT1A 5′-untranslated
region and a schematic representation of the constructed luciferase reporter promoters were presented. (B) Promoter activities of each deletion
construct in the absence or presence of GBE in the HepG2 cells. Luciferase activity was presented as a fold induction relative to pGL3-basic vector
whose value was set as 1. *P < 0.05 versus each respective control group (DMSO, D). #P < 0.05 versus DMSO treated group of pGL3-basic vector.
(C) Regulation of each deletion promoter construct in flavonoid-treated HepG2s. The luciferase activity in each group was calculated as a fold
induction relative to the untreated pCPT1A-3/Luc whose value was set as 1. *P < 0.05 and **P < 0.01 versus corresponding untreated construct.
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inflammatory and stress response-related genes were reg-
ulated through the integrated transcriptome and metabo-
lome profiles of GBE [4,15,16].
GBE and its flavonoid components – quercetin, kaemp-
ferol, and isorhamnetin – are widely found in fruits andvegetables. They reduce the hepatic lipid accumulation
and up-regulate the expression of CPT1A [5,17-19]. Pa-
tients with NAFLD had lower CPT1A expression and ac-
tivity [20]. In addition, physiological over-expression of
this rate-limiting enzyme in vivo and in vitro was sufficient
to prevent the fatty acid-induced lipid accumulation and
Figure 3 Functional analysis of Sp1 binding sites in the promoter of CPT1A. (A) Effect of Sp1 on activity regulation of CPT1A promoter
by GBE and its flavonoids. *P < 0.05 versus respective DMSO-treated construct. D, G200, Q20, K20, I8 represent HepG2 cells incubated with 0.1%
DMSO, 200 μg/ml GBE, 20 μg/ml quercetin, 20 μg/ml kaempferol, and 8 μg/ml isorhamnetin, respectively. (B) Illustration of constructs from
region −50 to −5 with mutation of putative Sp1 sites. The filled circles represent each SP1. (C) Site-directed mutation analysis of Sp1 in the
proximal promoter region of human CPT1A in HepG2 cells. Luciferase activity in each group was presented as a fold induction relative to
untreated wild construct (value was set as 1). Each value represents mean ± SD of three individual experiments; *P < 0.05 versus each control
treated group. (D) Mutation analysis of putative Sp1 binding sites in CPT1A promoter by flavonoids treatment. Values of luciferase activity
were presented as a fold induction relative to the DMSO-treated pCPT1A/WT (value was set as 1). *P < 0.05 and **P < 0.01 versus respective
DMSO-treated construct. Values were presented as mean ± SD of three experiments.
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characterize the probable molecular mechanisms by which
GBE and its flavonoids regulate CPT1A expression and
are hopeful in its potential benefits for treating NAFLD.
The majority of fatty acid oxidation in the liver occurs
in mitochondria and is regulated by CPT1A. We si-
lenced CPT1A in HepG2 cells through RNAi to impair
the oxidative capacity of mitochondria and observed a
significant increase in cellular triglyceride content. GBE
and its flavonoid contents – quercetin and kaempferol
minus isorhamnetin – lowered triglycerides without in-
fluencing CPT1A expression, which suggested there
were alternative pathways at play. β-oxidation was also
reported to occur in peroxisomes and microsomes [21].
GBE had also been reported to up-regulate a suite of
genes related to peroxisomes and microsomes oxidation
in an NAFLD rat model, such as straight-chain acyl-CoA
oxidase (Acox), PPARα, and cytochrome P450 enzym-
es, indicators of fatty acid consumption. Quercetin and
kaempferol were also confirmed to affect partial genes
[5,18-20,22]. Therefore, GBE and its flavonoids might in-
crease CPT1A expression to promote β-oxidation in mito-
chondria, as well as in peroxisomes and microsomes.
Human CPT1A is a TATA-less gene with GC-rich re-
gions in the proximal promoter. Sp1 is a ubiquitously-
expressed transcription factor belonging to a zinc finger
family and has an important role in directing transcriptionof the TATA-less genes [23,24]. In rat, Sp1 was found to
bind to the promoter of CPT1A and was responsible for
driving its basal expression [25]. Our observation also
confirmed Sp1 could affect the expression of CPT1A and
cellular triglyceride content (Additional file 1: Figure S1B
and C). In addition, we revealed for the first time a region
from −426 to +38 containing cis-elements for the basal
transcription of human CPT1A. Sp1 was most likely pre-
dicted to bind in region −50 to −5 through computer-
aided analysis. Other factors were also predicted, for
example, YY1, TBP, AP2, ERα had the ability to co-regulate
with Sp1 in TATA-less genes [26-29]. Therefore, Sp1 might
co-regulate basal transcription activity of CPT1A with vari-
ous transcription co-factors.
We identified an indispensable segment of GBE-acting
locus located at −50 to −5 with predicted Sp1 binding
sites and high-GC content using deletion and mutation
analysis. EMSA results demonstrated that GBE induced
a marked increase in DNA-protein complex formation
in this region. ChIP analysis confirmed the GBE-induced
binding of Sp1 in intact cells. The flavonoid ingredients
also obtained the same responsive element with GBE.
These findings suggested that the presence of Sp1 bind-
ing region between −50 and −5 was important for GBE-
induced regulation of CPT1A as well as the flavonoids.
Sp1 activity is significantly regulated through post-trans-
lational modifications, including glycosylation, acetylation,
Figure 4 Regulation of Sp1 by GBE. (A) mRNA expression of Sp1 regulated by GBE in HepG2 cells. (B) Protein expression of Sp1 regulated by
GBE in HepG2 cells. β-actin was used as control. (C) Expression analysis of Sp1 in cytoplasm and nucleus regulated by GBE. Expression of cytoplasmic
Sp1 was normalized to α-tubulin. Expression of nucleus Sp1 was normalized to histone H3. D, G200, Q20, K20, I8 represent HepG2 cells incubated with
0.1% DMSO, 200 μg/ml GBE, 20 μg/ml quercetin, 20 μg/ml kaempferol, and 8 μg/ml isorhamnetin, respectively.
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through ERK, JNK, and p38-MAPK signaling pathways
[32,33]. Quercetin and isorhamnetin, ingredients of GBE,
were found to induce genes through these pathways
[34-36]. Thus, in hepatic cells, GBE and its flavonoid com-
pounds might activate Sp1 through mitogen-activated and
protein kinase-mediated signal transduction pathways.
Sp1 also proved to be involved in regulating multiple
transcription processes. In human endothelial cells, it
was indispensable that enhanced binding of Sp1 to thepromoter region of tissue-type plasminogen activator
(t-PA) in quercetin induced expression through a p38-
dependent pathway [34]. Additionally, quercetin could
lead to binding of Sp1 to ABCA1 [37] and significantly
up-regulate DR5, a death receptor of TRAIL, in a tran-
scription factor, Sp1-dependent manner [38]. Moreover,
other flavonoids like genistein and daidzein were also
reported to target genes in the GC-rich Sp1 binding se-
quence in intestinal cells [39]. Nobiletin, another citrus
polymethoxylated flavonoid, regulated the bacterial
Figure 5 Analysis of Sp1 response element in CPT1A promoter region. (A) Electrophoretic mobility shift assay (EMSA) was performed for
identification of Sp1 binding to the CPT1A promoter region from −50 to −5 in vitro. DNA-protein complexes were formed upon addition of
nuclear extracts from vehicle or GBE-treated HepG2s (lane 2, 3). The binding specificity was competed by excess (×100) unlabeled (cold) probes
(lane 4). (B) For supershift, binding reactions were carried out in the presence of antibodies against Sp1 or non-immune goat IgG (negative
control). (C) ChIP analysis in HepG2 cells showed that GBE induced Sp1 to the indicated binding sites. Left panel, input control (for each group,
0.15 μg DNA was used for PCR); middle panel, Sp1 immunoprecipitation; and right panel, IgG immunoprecipitation (negative control). PCR was
performed as described in Chromatin Immunoprecipitation Assay (ChIP) Section and products were run on a 2.0% agarose gel. D, G200, Q20, K20,
I8 represent HepG2 cells incubated with 0.1% DMSO, 200 μg/ml GBE, 20 μg/ml quercetin, 20 μg/ml kaempferol, and 8 μg/ml isorhamnetin,
respectively.
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factor (TF) through interaction with Sp1 [40].
In addition to regulating Sp1, natural products could
also be involved in regulating other transcription factors.
Flavonoids like genistein, kaempferol, quercetin, and
daidzein inhibited STAT-1 and NF-kappa B activations
in anti-inflammatory effects [41]. The regulatory effect
of quercetin on two main transcription factors (NF-
kappa B and AP-1) was also investigated and found to
related to survival/proliferation pathways in a human
hepatoma cell line [42]. Other natural products like caf-
feic acid phenethyl ester was also reported to interact
with NF-kappa B [43]. From this we could see that regu-
lation of transcription factors might be a mechanism of
action of natural products.
Conclusion
We have shown that a direct and specific increase in
CPT1A plays a crucial role in GBE and its flavonoids’effects. GBE, as well as quercetin, kaempferol, and iso-
rhamnetin, up-regulate CPT1A through interaction with
Sp1 to promote fatty acid β-oxidation and further exert
their lipid-lowering effect. Better understanding of this
mechanism may provide implications in GBE application
and treatment approaches for related metabolic diseases.
Additional file
Additional file 1: Figure S1. Expression of CPT1A and the cellular
triglyceride content after knockdown of Sp1 in HepG2 cells. (A) mRNA and
protein expression of Sp1. (B) mRNA and protein expression of CPT1A.
(C) The cellular triglyceride content. NC represented negative control.
The cellular triglyceride content in NC group was set as 100%, and values
in other groups were compared to it. *P < 0.05 versus NC group.
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